Australia Markets open in 8 hrs 58 mins

Aptinyx Inc. (APTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5931-0.0286 (-4.60%)
At close: 04:00PM EDT
0.5931 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6217
Open0.6386
Bid0.5851 x 1100
Ask0.6179 x 1800
Day's range0.5626 - 0.6386
52-week range0.5600 - 4.7300
Volume432,618
Avg. volume449,262
Market cap40.162M
Beta (5Y monthly)1.09
PE ratio (TTM)N/A
EPS (TTM)-1.0270
Earnings date22 Mar 2022 - 28 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.33
  • Business Wire

    Aptinyx to Participate in H.C. Wainwright Global Investment Conference

    EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.

  • Business Wire

    Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

    EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.

  • Motley Fool

    Aptinyx Inc. (APTX) Q1 2022 Earnings Call Transcript

    On today's call, Andy Kidd, our president and chief executive officer, will discuss our business and clinical development progress; then Ashish Khanna, our chief financial officer and chief business officer, will review our financial results. Please see the forward-looking statement disclaimer in our financial results release issued this afternoon and the risk factors in the company's current and subsequent filings with the SEC.